Navigation Links
MGC Diagnostics Corporation Reports 2013 Second Quarter Operating Results
Date:5/30/2013

SAINT PAUL, Minn., May 30, 2013 /PRNewswire/ -- MGC Diagnostics Corporation (NASDAQ: MGCD) (formerly Angeion Corporation), a global medical technology company, today reported financial results for the second quarter ended April 30, 2013.

(Logo: http://photos.prnewswire.com/prnh/20120821/LA60189LOGO)

Second Quarter Highlights:

  • Robust second quarter revenue of $7.6 million, an increase of 35% over the fiscal 2012 second quarter. Sequential quarterly revenue growth of 8% from the first quarter of fiscal 2013;
  • Net income for the second quarter was $252,000, or $0.06 per diluted share, compared to a net loss of $409,000, or ($0.11) per diluted share in the 2012 second quarter;
  • Group Purchasing Organization ("GPO") sales increased 69% to $3.9 million, compared to $2.3 million in the 2012 second quarter;
  • Second quarter service revenue increased 8% on a year-over-year basis, while service gross margin improved to 70.3%, compared to 64.2% in the fiscal 2012 second quarter; 
  • Gross margin in the second quarter improved 210 basis points to 55.7%, compared to 53.6% in last year's second quarter;
  • The Attachment Rate of extended service contracts sold at the point of system sale improved to 27.4%, compared to 6.2% in last year's second quarter;
  • Second quarter 2013 recurring revenue (service and supplies revenues) totaled $2.6 million, or 35% of total second quarter revenue;
  • The Company declared and paid a special, one-time cash dividend of $0.45 per share during the quarter;
  • Strong balance sheet with $8.2 million in cash and cash equivalents, $12.4 million of working capital and no long-term debt after payment of the $1.8 million dividend;
  • At April 30, 2013, the Company had federal net operating loss carry f
    '/>"/>

  • SOURCE MGC Diagnostics Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Apnix Sleep Diagnostics Announces New Houston Sleep Apnea Treatments
    2. Alzheimer Market: Drugs, Therapeutics & Diagnostics Research Reports
    3. MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013
    4. Exosome Diagnostics Presents Data Demonstrating Utility of Urine Exosome Technology to Predict Prostate Biopsy Outcome at American Urological Association Annual Meeting
    5. Algeta and Lumiphore Announce Further Expansion of Their Global Partnership for the Development of Targeted Alpha-pharmaceutical Cancer Therapeutics and Companion Diagnostics.
    6. BD Diagnostics Advances Commitment to a Fully Integrated Microbiology Solution with New Agreement
    7. Apnix Sleep Diagnostics Offering New Home Sleep Study Materials
    8. LamdaGen Corporation Issued United States Patent for Diagnostics on Plasmonic-Based Nanosensors
    9. Nipro Diagnostics Leverages Managed IT Services from JDL Technologies to Support Growth and Technological Innovation
    10. 2013 Cancer Diagnostics Market Analysis: Cancer Testing Industry Growing Rapidly
    11. Quest Diagnostics Reports First Quarter 2013 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/24/2014)... 24, 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a ... announced its financial results for the second quarter ended June ... , Total revenues of $6.5 million in the second quarter ... in 2013 , Total revenues of $13.3 million for ... 78% over the same period in 2013 , Total ...
    (Date:7/24/2014)... July 24, 2014 LSI Medience Corporation ... Agreement with Kineticos, a Raleigh-Durham, NC ... will support LSI Medience in identifying opportunities for ... demonstrate utility in clinical trials. The ... in diagnosis of sepsis, prognosis of septic patients, ...
    (Date:7/24/2014)... , July 24, 2014  The American ... is supporting its mission to help address audit ... and exclusive agreement to be the information technology ... As the leading provider of billing and business ... unmatched HME industry expertise to support this important ...
    Breaking Medicine Technology:IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Brightree Joins AAHomecare as Corporate Partner and IT Lead on HME Audit Key 2
    ... ONXX ) today announced that it will present at the Canaccord ... a.m. Eastern Time ( 5:00 a.m. Pacific Time ). , ... Interested parties may access a live webcast of the presentation on our website ... It is recommended that ...
    ... Aug. 3 On June 9, 2010 , Invivo was recognized ... and DynaTRIM (Trans-Rectal Interventional MRI) clinical solutions. The MDEA awards ceremony took place in ... gold and silver winners were honored. , , ... (Photo:   http://photos.prnewswire.com/prnh/20100803/SF44927 ) , , , ...
    Cached Medicine Technology:Onyx Pharmaceuticals to Present at the Canaccord Genuity 30th Annual Growth Conference 2Invivo Wins Medical Design Excellence Award for Prostate Solutions 2Invivo Wins Medical Design Excellence Award for Prostate Solutions 3
    (Date:7/25/2014)... CA (PRWEB) July 25, 2014 DON’T PAUSE ... help alleviate uncomfortable bloating, hot flashes, mood swings, burning ... identified by Dr. Shoreh Ershadi. The AntiAging Institute of California ... Menopause that allows women to try this revolutionary product. For ... PAUSE can get a third bottle at no charge. ...
    (Date:7/25/2014)... and desires in initial romantic encounters determine the fate ... those initial "sparks" necessary to fuel sexual desire and ... a desirable trait for both men and women on ... the other person? Do men perceive responsive women as ... women,s perceptions of men? A study published in ...
    (Date:7/25/2014)... Researchers at the University of Bordeaux in Bordeaux, France have ... man-made material used in high-heat insulation may increase the risk ... has just posted an article on the new study. ... French scientists studied the work histories of 988 men ... group of workers had been exposed to asbestos only while ...
    (Date:7/25/2014)... York, NY (PRWEB) July 25, 2014 ... for the Guinness International Champions Cup Match between Manchester ... Bronx, New York, one of the most iconic locations is ... original Yankee Stadium, but it is quickly becoming a location ... The facility is home to the New York Yankees from ...
    (Date:7/25/2014)... 25, 2014 CMS recently has imposed ... for providing inadequate access to prescription drugs. Agency audits ... health and safety of beneficiaries in areas such as ... and CMS is taking quick and firm actions to ... Services webinar, “Avoiding Costly Part D Sanctions: Rx ...
    Breaking Medicine News(10 mins):Health News:AntiAging Institute of California Now Offers DON'T PAUSE for Menopause with a Special Promotion 2Health News:Why do men prefer nice women? 2Health News:Why do men prefer nice women? 3Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 2Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 3Health News:Manchester City vs. Liverpool FC Tickets Yankee Stadium: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match in NYC on July 30th 2Health News:Manchester City vs. Liverpool FC Tickets Yankee Stadium: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match in NYC on July 30th 3Health News:Aug. 5 Webinar to Offer Strategies for Preventing Rx Access Issues and Avoiding Part D Sanctions 2
    ... , NASHVILLE, Tenn. and GLEN ROCK, N.J., ... 76 percent of surveyed pharmacy directors say that by ... only one preferred biologic for all immune conditions, such ... According to the new Formulary Forum report entitled ...
    ... , , , ... GHDX ) today announced that Kim Popovits, Genomic Health,s Chief ... Growth Conference in Boston, on Thursday, August 13 at 1:30 p.m. ... subsequently archived webcast of the presentation, visit the Investor Relations section ...
    ... , , HOUSTON, Aug. 6 ... a Phase I/II clinical trial of BP-GMAX-CD1, a novel pharmacologically regulated ... trial is being conducted under a Bellicum Investigational New Drug application ... results of the study in 2010. , , ...
    ... , , KIBBUTZ SHAMIR, ... SHMR ) (" Shamir ") expects to issue its second quarter ... a conference call to discuss the results at 11:00 A.M. EDT that ... broadcast live as a listen-only webcast. To listen live, please go to ...
    ... , , NEW YORK, ... synthetic peptide technology shown to significantly help improve the appearance of ... now available through select physicians to help their patients achieve picture ... can be found in leading physician offices for $120 per 1 ...
    ... , SALT LAKE CITY, Aug. 6 ... silicon nitride ceramic technologies, announced today that Ben Shappley has joined ... Shappley will also serve on the company,s Board of Directors. , ... of orthopaedic and neurosurgical implant experience in both management and senior ...
    Cached Medicine News:Health News:U.S. Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 2Health News:U.S. Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 3Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 2Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 3Health News:Shamir Optical Industry Ltd. to Host Conference Call Announcing Second Quarter of 2009 Earnings Results 2Health News:Photos: Lumixyl(TM) Enters the Market to Improve the Appearance of Hyperpigmentation without Irritation and Side Effects 2Health News:Photos: Lumixyl(TM) Enters the Market to Improve the Appearance of Hyperpigmentation without Irritation and Side Effects 3Health News:Ben Shappley Joins Amedica's Leadership Team 2
    ... a differential medium designed for the ... Selective agents are incorporated for the ... of S. epidermidis and yeast. S. ... in mauve colonies, thus permitting differentiation ...
    The Linvatec 3mm and 5mm Universal Light Guides are autoclavable. They offer flexibility, superior light transmission, and universal fittings in a lightweight package....
    ... a 180 watt Xenon short arc lamp. Designed to ... the lamp to the light guide, this light source ... higher watt bulbs. A new IR filtering system and ... amount of heat generated from the light source and ...
    ... standardize your video equipment has led Linvatec ... couplers to accommodate all of your multi-specialty ... "V mount couplers in both traditional eyecup ... also offer a 20-42mm Zoom "C mount ...
    Medicine Products: